Bristol-based Wanda Health, an intelligent platform for Remote Patient Monitoring (RPM) and Virtual Care, has successfully closed an investment round of €2.1 million in order to reduce hospitalisations and readmissions by collecting real-time data from patients at home or in community settings, and alerting clinicians to high-risk individuals.
The funding includes €960k raised through EIS investments, a combination of debt and CLA (Convertible Loan Agreement) conversions, and an additional €287k secured through a loan facility. The announcement was shared by the DeepTech and life sciences VC investment group EMV Capital plc, which counts Wanda Health among its portfolio companies.
Tom Smith, Chief Executive Officer of Wanda, said: “With new funding in place and key partnerships progressing well, we are now scaling our impact across the US. With the additional capital, we are well positioned to capitalise on the growing opportunities in the rapidly expanding digital remote monitoring market and to move closer to our mission of best-in-class intelligent virtual care.”
Founded in 2014, Wanda Health is an intelligent platform for remote patient monitoring and virtual care. The company builds on research from UCLA developed technologies focused on intelligent remote monitoring of physiological data, patient engagement and healthcare analytics for post-acute care, chronic disease patients and population health.
Wanda’s platform aims to enable the control and reduction of hospitalisation and readmission rates through a Remote Patient Monitoring System that collects data from patients’ homes or community settings and provides it to clinicians, highlighting high risks cohorts.
Wanda also uses its comprehensive multi-modality patient engagement tools to ensure that adherence to treatment protocols increases, improving patient outcomes.
“Once fully onboarded, our existing contracts are projected to provide over $3.5 million ARR, at which point we will target a Series A investment round. At that time, we expect our business to have a significantly higher valuation.
“We are incredibly grateful to EMV Capital for their continued belief in Wanda’s mission. As a long-standing partner, their trust, insight, and support have been instrumental in helping us reach our next stage of growth. Closing this round with their backing reinforces our shared vision of transforming how people engage with their health. We are excited for what lies ahead – and proud to have EMV Capital with us on the journey,” added Smith.
Earlier in the year, Wanda secured partnerships with the COPD Foundation and the American Heart Association, strengthening the company’s access to key clinical opinion leaders in core focus areas.
In the first half of the year, Wanda closed a new contract with Sav-Rx, a US PBM serving a network of over 65,000 pharmacies across the US, and which has the potential to achieve multi-million ARR for the company. Onboarding has already started.
Wanda’s Provider Business is performing well, with an additional four new provider sites undertaking Medicare RTM; RPM; and CMM programmes with the company across Sleep Apnoea, Pain Management and General Chronic Disease Management.
Wanda has also onboarded a group of assisted living facilities across California, which is a new use case for its team. The combined total of anticipated patient ramp-up equates to €259k, realised at the end of 2025. Again, this revenue is recurring.
Dr Ilian Iliev, Chairman of Wanda and CEO of EMV Capital plc commented: “We are delighted to support Wanda as it continues to develop and build out its platform, customer base, market strategy, and leadership team. With growing demand and a clearly defined regulatory pathway, the company is continuing well on its growth journey. We look forward to seeing Wanda’s impact grow, as it scales its operations across the US, and beyond.”
Read the orginal article: https://www.eu-startups.com/2025/08/british-healthtech-startup-wanda-health-raises-e2-1-million-to-scale-intelligent-virtual-care-and-reduce-hospital-readmissions/
